Biology, vulnerabilities and clinical applications of circulating tumour cells
In recent years, exceptional technological advances have enabled the identification and
interrogation of rare circulating tumour cells (CTCs) from blood samples of patients, leading …
interrogation of rare circulating tumour cells (CTCs) from blood samples of patients, leading …
Clear cell renal cell carcinoma ontogeny and mechanisms of lethality
The molecular features that define clear cell renal cell carcinoma (ccRCC) initiation and
progression are being increasingly defined. The TRACERx Renal studies and others that …
progression are being increasingly defined. The TRACERx Renal studies and others that …
[HTML][HTML] The evolution of lung cancer and impact of subclonal selection in TRACERx
Lung cancer is the leading cause of cancer-associated mortality worldwide. Here we
analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 …
analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 …
Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness
Clear cell renal cell carcinomas (ccRCCs) represent∼ 75% of RCC cases and account for
most RCC-associated deaths. Inter-and intratumoral heterogeneity (ITH) results in varying …
most RCC-associated deaths. Inter-and intratumoral heterogeneity (ITH) results in varying …
Cancer evolution: Darwin and beyond
Clinical and laboratory studies over recent decades have established branched evolution as
a feature of cancer. However, while grounded in somatic selection, several lines of evidence …
a feature of cancer. However, while grounded in somatic selection, several lines of evidence …
Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy
Clear cell renal cell carcinomas (ccRCCs) are highly immune infiltrated, but the effect of
immune heterogeneity on clinical outcome in ccRCC has not been fully characterized. Here …
immune heterogeneity on clinical outcome in ccRCC has not been fully characterized. Here …
Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer
Circulating tumour DNA (ctDNA) in blood plasma is an emerging tool for clinical cancer
genoty** and longitudinal disease monitoring. However, owing to past emphasis on …
genoty** and longitudinal disease monitoring. However, owing to past emphasis on …
Integrating genetic and non-genetic determinants of cancer evolution by single-cell multi-omics
Cancer represents an evolutionary process through which growing malignant populations
genetically diversify, leading to tumour progression, relapse and resistance to therapy. In …
genetically diversify, leading to tumour progression, relapse and resistance to therapy. In …
The immunology of renal cell carcinoma
Renal cell carcinoma (RCC) is the most common type of kidney cancer and comprises
several subtypes with unique characteristics. The most common subtype (~ 70% of cases) is …
several subtypes with unique characteristics. The most common subtype (~ 70% of cases) is …
Genetic and non-genetic clonal diversity in cancer evolution
The observation and analysis of intra-tumour heterogeneity (ITH), particularly in genomic
studies, has advanced our understanding of the evolutionary forces that shape cancer …
studies, has advanced our understanding of the evolutionary forces that shape cancer …